I appreciate the opportunity to review the protocol titled, "Incentives to Quit Tobacco in Pregnancy (iQuiP)," which describes a research plan to deliver a financial incentives intervention as part of routine care among a high-risk pregnancy population. This work is challenging but very important, and I commend the authors for selecting what meta-analyses have shown to be the most effective approach to promoting smoking cessation in pregnant women as their intervention. However, I have some concerns about the authors' proposal, and also about aspects of the present protocol as it is currently written. Because the present submission represents a protocol and authors can therefore still revise it, most of these comments should be addressable in a revision. I have outlined these major and minor concerns in greater detail below.
MAJOR CONCERNS:
-Summary page: In the Research Summary section, please consider adding a statement about length of treatment (e.g., from first prenatal care visit through 12 weeks postpartum). Currently authors no not appear to state how long treatment lasts.
-Summary page: Objective #3 should clarify that authors are assessing acceptability of tobacco cessation services as part of routine care among this Aboriginal population specifically. It currently reads as if this is the first attempt to examine this question in general, however feasibility and cost-effectiveness of implementing incentives as part of routine prenatal care has already been examined in the UK.
-Introduction: In summarizing the effectiveness of financial incentives targeting smoking cessation among pregnant women, authors should also state the positive benefits observed on infant health outcomes (e.g., see Higgins et al. 2012 for data indicating higher birth rates, fewer LBW infants and NICU admissions), and consider also referencing Boyd et al. suggesting that the intervention is cost-effective. Please also consider referencing meta-analyses by Lussier et al. 2006, Chamberlain et al., Cahill et al. showing incentives to be more effective than other psychosocial or pharmacological approaches to promoting smoking cessation.
-Introduction should also include some statements about higher rates of smoking cessation among people with other substance use disorders, mention other research that has targeted pregnant smokers using other substances (e.g., Tuten et al.) , and highlight how deploying an intervention to a subpopulation of pregnant smokers with comorbid SUD's has been under-examined.
-Authors state that, "There is yet to be consensus regarding specific scheduling and magnitude of rewards.." (pg. 6), but this statement is not exactly correct. Lussier et al. meta-analysis, for example, shows that magnitude and delay are the two significant moderators of effect sizes/efficacy in incentives interventions. The author seems to acknowledge this several sentences later, so I would recommend perhaps revising or deleting the sentence above to avoid confusion.
-Author spends much of the Introduction focused on incentives. This makes sense in terms of the fact that meta-analyses show incentives to be most effective, however the author's proposal includes other components as well. In particular, the author should discuss the rationale and supporting data for NRT, as this approach has shown mixed efficacy in pregnant women and therefore it is not clear why including NRT is necessary or expected to be helpful beyond incentives alone.
-Consider providing more rationale for use of this specific counseling approach, and perhaps explain BAT and provide supporting references without mentioning Al Baker by name. This was somewhat unconventional and some readers may not recognize this person by name.
-Is there a way that participants can be compensated more quickly for their specimens? (e.g., reloadable study debit cards)-Paying them once weekly for samples submitted daily is not ideal, as it involves a longer delay that is likely to compromise effectiveness. If there are logistical reasons this is necessary, consider stating those in the text.
-Incentives should be based on the biochem data alone-Why would participants accurately report yes to smoking if it will cost them their voucher? In CM studies, light smokers who may fly under the radar at first and earn some money eventually will get caught.
-It is unclear why 3 ppm is the cutoff for entering the study as a smoker-This is lower than the author's abstinence criterion. Also, as I understood it, participants have a few days of baseline CO monitoring before they start receiving incentives. If a pregnant women is reliably blowing 4's and 5's, the authors will not be able to show treatment effectiveness within subjects because the woman will already be meeting the abstinence criterion.
MINOR CONCERNS:
-Authors might consider revising the title to convey that the target sample is pregnant smokers with comorbid substance use disorders.
-Summary page: Eligibility criterion #1 is difficult to read, and I am not sure what the criterion means.
-Consider stating what type of CO monitor is being used in the study.
-Seems like a lot of resets needed to restore participants to the value they were at before they had a slip-Authors should cite any prior protocols or research studies on which that decision was based.
-Are there any inclusion guidelines or analyses planned that take into account the specific type and frequency of other substance being used? It seems that the author may end up with a somewhat variable group, and it seems important to take into account what are the other substances that participants are using, and how often.
-Patient risks section does not say anything about the security of their electronic data and submission of the videos to the researchers.
REVIEWER
Mai Frandsen University of Tasmania Australia REVIEW RETURNED 29-Jun-2019
GENERAL COMMENTS
This protocol describes a timely, important and innovative study investigating the feasibility of combining contingency management with other evidence-based smoking cessation treatments to promote smoking cessation among a vulnerable group of smokers traditionally are not motivated to quit tobacco smoking -substance using pregnant women. The protocol is sound however, please consider the below points: 1. The schedule appears extremely involved. The purpose of the study is to measure feasibility, however, as the program is described, you would needs at least 1-2 people employed just to monitor people's progress. In addressing Reviewer 1's comments, it was apparent that most comments were directed at the protocol document that had been included as supplementary material. We acknowledge that due to the time since it was written, a lengthy ethics process and numerous variations, the protocol contained errors and an outdated background that were not reflected in the protocol manuscript. To rectify this, the protocol document has now been updated. These changes have been submitted to our ethics committee for approval. Thank you for your thorough review, individual comments have been addressed below. Summary Page: 1.
In the Research Summary section, please consider adding a statement about length of treatment (e.g., from first prenatal care visit through 12 weeks postpartum). Currently authors no not appear to state how long treatment lasts. Thank you highlighting this. A section outlining treatment length for participants has been added to the protocol summary. 2.
Objective #3 should clarify that authors are assessing acceptability of tobacco cessation services as part of routine care among this Aboriginal population specifically. It currently reads as if this is the first attempt to examine this question in general, however feasibility and cost-effectiveness of implementing incentives as part of routine prenatal care has already been examined in the UK. Objective #3 does outline the acceptability of the intervention but there is no indication that it is the first to do so. Although this is not an aboriginal population, it is focused on a population of pregnant women with a range of substance use problems, not specifically opiates as was the case in the UK. Moreover, evaluating the interventions acceptability, feasibility and cost-effectiveness is critical to understanding how it translates into the Australian health context. For clarity, the objectives have been re-worded in the protocol document summary section (page 4) and section 3.2 (page 7) to read: Primary objectives:
Assess the feasibility of addressing tobacco smoking amongst this population using a combination of contingency management, NRT and behavioural counselling. II.
Evaluate the acceptability of offering treatment for tobacco dependence, and of the intervention components, among participants and staff of substance use in pregnancy antenatal services. Secondary objectives: I.
Examine changes in tobacco smoking behaviours of study participants. Behaviours include self-reported and carbon monoxide (CO) validated abstinence and reduction, quit attempts and home smoking bans. II.
Compare adverse maternal outcomes of study participants to those of a historical control group. III.
Compare neonatal outcomes of infants born to study participants to those of a historical control group. IV.
Financially evaluate the costs and benefits of implementing the intervention.
Introduction: 3.
In summarizing the effectiveness of financial incentives targeting smoking cessation among pregnant women, authors should also state the positive benefits observed on infant health outcomes (e.g., see Higgins et al. 2012 for data indicating higher birth rates, fewer LBW infants and NICU admissions), and consider also referencing Boyd et al. suggesting that the intervention is costeffective. Please also consider referencing meta-analyses by Lussier et al. 2006, Chamberlain et al., Cahill et al. showing incentives to be more effective than other psychosocial or pharmacological approaches to promoting smoking cessation. and 4.
The Introduction should also include some statements about higher rates of smoking cessation among people with other substance use disorders, mention other research that has targeted pregnant smokers using other substances (e.g., Tuten et al.), and highlight how deploying an intervention to a subpopulation of pregnant smokers with comorbid SUD's has been under-examined. As mentioned above, the protocol document background has been updated (pages 5-7) and contains the most current references (including those mentioned here) and information pertaining to smoking in substance use populations. 5.
Consider providing more rationale for use of this specific counselling approach, and perhaps explain BAT and provide supporting references without mentioning Al Baker by name. This was somewhat unconventional, and some readers may not recognize this person by name. The protocol contains a list of investigators and the terms Associate Investigator (AI) and Chief Investigator (CI) have been used throughout the document as they are considered a conventional term for use in a protocol in Australia. These terms have not been included in the protocol manuscript. 6.
Is there a way that participants can be compensated more quickly for their specimens? (e.g., reloadable study debit cards)-Paying them once weekly for samples submitted daily is not ideal, as it involves a longer delay that is likely to compromise effectiveness. If there are logistical reasons this is necessary, consider stating those in the text. This point was also raised by the 2nd reviewer and we would like to acknowledge that this was an important consideration in the development of this intervention. Bound by the inflexibility of fixed amount gift cards, we sought advice from contingency management researchers (both local and international) who suggested that instant feedback about incentives earned should be sufficient to maintain motivation. The use of feedback as a bridge between earning and receipt of earnings has been successfully trialled in the past and is supported by published data (see Reynolds, Dallery et al. 2008) . Given that both reviewers have highlighted what will potentially be a common question, we have added additional rationale to that already mentioned on page 10 of the protocol manuscript. The incentives section on page 9, line 5 of the manuscript now reads:
Incentives will be in the form of electronic gift cards from a major retail outlet that may be exchanged for groceries and general merchandise but restricted for purchases of alcohol and tobacco products. Due to the frequency of sampling and constraints of fixed amount gift cards, participants will receive written notification of incentive amounts earned immediately after submission of each CO sample. This methodology provides the positive reinforcement required to maintain behaviour change and has been successfully employed in an incentives program for adolescent smoking cessation.73 Actual earnings will be distributed weekly or accumulated and redeemed at a participant's request. 7.
Incentives should be based on the biochem data alone-why would participants accurately report yes to smoking if it will cost them their voucher? In CM studies, light smokers who may fly under the radar at first and earn some money eventually will get caught. The logic around this point is understood. However, due to the many concerns raised by the approving ethics committee around gaming and deception, it was decided that participants should confirm their smoking status, so that light smokers were not seen to be incentivised. It is likely they will only answer 'yes' once before recognising the consequences, but this provides a unique opportunity to address smoking again and discuss other appropriate strategies to help stop. It came to our attention that this small piece of information was not in the protocol manuscript, so the wording about submitting CO samples has been amended (page 9, line 23) and now reads: Results will be submitted by completing a short survey sent prior to each expected test. These require the samples' date, time, and ppm value and confirmation of current smoking (yes/no) as well as the time-and date-stamped video footage to be uploaded for confirmation by the research team. 8.
It is unclear why 3 ppm is the cut-off for entering the study as a smoker-this is lower than the author's abstinence criterion. Also, as I understood it, participants have a few days of baseline CO monitoring before they start receiving incentives. If a pregnant woman is reliably blowing 4's and 5's, the authors will not be able to show treatment effectiveness within subjects because the woman will already be meeting the abstinence criterion. In earlier protocol versions our abstinence criterion was ≤3ppm but feedback suggested that this level might be problematic to keep up motivation given the prevalence of partner and household smoking. It was raised to ≤5ppm but the eligibility criteria were kept at ≤3ppm to ensure that we could offer the intervention to any smoking clients, even those registering as light smokers at screening. In our own clinic, it is evident that most pregnant women in this group do smoke and that smoking levels fluctuate throughout their pregnancy. 9.
Authors might consider revising the title to convey that the target sample is pregnant smokers with comorbid substance use disorders. Thank you for your suggestion and in hind sight, the original protocol title should have included the population group. The protocol document title has been updated with the additional wording: Piloting a financial incentive-based smoking treatment for women attending substance use in pregnancy antenatal services (Protocol document, page 1). 10.
Summary page: Eligibility criterion #1 is difficult to read, and I am not sure what the criterion means. Apologies for the lack of clarity. It appears that the word 'or' has been omitted or deleted from the sentence. The protocol document summary (page 4) and section 5.3 (page 14) have been amended and now read: 1) Pregnant women attending or referred to substance use in pregnancy antenatal services up to 32 weeks' gestation 11.
Consider stating what type of CO monitor is being used in the study. When the protocol was originally written, we were unsure what type of CO monitor were being purchased for the study. We have since purchased the Bedfont Micro+™ Smokerlyzer®. The protocol document has been amended to reflect this (page 9). 12.
Seems like a lot of resets needed to restore participants to the value they were at before they had a slip-Authors should cite any prior protocols or research studies on which that decision was based.
We thank the reviewer for recognising this error that has been overlooked during every iteration of the protocol document. The sentence 'Two consecutive weeks of negative samples will return the reward to its pre-reset value' should read 'Two consecutive negative samples will return the reward to its prereset value'. This has now been amended in the Protocol document, Figure 1 (page 10) and Section 4.2.2.2 (page 11). The incentives component of the study has been based on schedules used in previous internet based contingency management studies that utilise a two consecutive sample reset contingency, including Dallery et al., (2007) and Higgins et al., (2004) . Our intervention has been setup to reflect this and not two weeks of consecutive samples. This mistake has been rectified in the current protocol variation submission. Please note that the correct wording was used and above studies cited in the protocol manuscript.
13.
Are there any inclusion guidelines or analyses planned that take into account the specific type and frequency of other substances being used? It seems that the author may end up with a somewhat variable group, and it seems important to take into account what are the other substances that participants are using, and how often. The inclusion guidelines do not take into account any specific type or quantity of substance. Eligibility states that women must be referred to or attending a substance use in pregnancy antenatal service. Referral to these services are made by health service providers or child protection services because of known or self-disclosed substance use in current or previous pregnancies. The ATOP is being used to screen substance use (type and quantity) at baseline and at four-weekly intervals whilst on the study. 14.
Patient risks section does not say anything about the security of their electronic data and submission of the videos to the researchers. Although not covered in the Patient Risk section, the security of participant information collected as part of the study data has been covered in Section 10: Patient Protection of the protocol document (page 20).
Reviewer 2 1. The schedule appears extremely involved. The purpose of the study is to measure feasibility, however, as the program is described, you would need at least 1-2 people employed just to monitor people's progress. Do the researchers think it would ever be feasible for such a program to be implemented within existing perinatal services? What is the real-world feasibility of this intensive schedule/program? We would like to acknowledge these concerns and that they have been considered by the investigators of this study. Despite their effectiveness, contingency management programs for behaviour change are often complex and expensive to implement in real world settings. Fortunately, advances in technology are able to overcome some of these challenges. This pilot program has been designed using REDCap to automate as many of the CO monitoring processes as possible. While this has been labour intensive and is not purpose built, it has been inexpensive and will ease the impact on human resources while the program is running. It is envisaged that future implementation of the program would utilise a professionally produced mobile phone application with the ability to streamline processes further. Additionally, new technologies have created more practical smartphone enabled personal CO monitors to simplify monitoring procedures further. Regardless, such an intensive program will inevitably require a person responsible for monitoring, providing cessation support and tailoring nicotine replacement therapy to clients. With regard to the real world feasibility of this intervention, similar internet-based financial incentive programs have been successfully trialled in the US for smoking cessation across a range of populations. We acknowledge that there may be cultural differences and other challenges that limit its generalisability to the current target population and this is the purpose of piloting the intervention. Finally, we would also like to add a note about the participant interaction with the intensive schedule. Participants are not required to remember the intricacies of the intervention design. Completion of a CO each day will provide feedback to guide them to the time frame and earning potential of their next sample. Where required, verification and support will also be provided by a research team member using SMS or a phone call. 2. While CO has a short half-life, and I appreciate the reasoning behind 2 samples daily, previous incentive studies have demonstrated that the instance of 'gaming' is only around 5%. I question the necessity of such an intensive (resource wise, and demand on participants) schedule when the risk of people 'cheating' is so low. We carefully considered the twice daily schedule during protocol development as we did not wish to burden participants. The decision to go ahead with it was based on the fact that: (a) Twice daily assessment of CO is considered to be the gold standard to accurately measure smoking status; (b) excellent compliance rates for samples at this frequency have been noted in previous research; and (c) While the incidence of gaming is low, our approving ethics committee were very concerned about the possibility of false reporting of smoking status (and falsifying smoking status to gain entry into the program). We capped the twice daily regime to 4-weeks based on evidence that no smoking in the initial stages of a quit attempt is highly predictive of long-term abstinence. Regarding the demand on participants, CO samples take only 1-2 minutes to complete and upload and we do not believe that a twice-daily regime will overly burden them. If it should be a problem, it will certainly be highlighted as part of the feasibility assessment. 3. The schedule includes distinct phases with distinct time periods -Baseline (5 days), Reduction (~28 days), Abstinence (~28 days), and Thinning (28 days prior to EDD) -and it is unclear from the protocol how researchers will adjust to participants who enter the program at different gestation. What if someone enters at 31 weeks, does Baseline still go for 5 days, Reduction for 28? We would like to thank the reviewer for highlighting this as it was something that was not set out clearly. Wording has been added to the reinforcement schedule of the manuscript (page 11 - Table 1 ) and the protocol document (page 9) for clarification. The optional reduction phase is now clearly marked as such. The thinning stage will only apply to those women who have completed at least 6 weeks of abstinence. This is included in the latest variation to the current protocol document. Based on this, a woman entering the study at 31 weeks will do up to 5 days of baseline and chose to reduce slowly (for up to 28 days) or attempt to quit and go onto the abstinence phase. If she is abstinent for 6 weeks, then she would go to thinning at approx. 38 weeks gestation. 4. It was also unclear if incentives/CO monitoring continues post-partum -the time period where many women relapse to smoking. Again, we would like to thank the reviewer for highlighting this oversight, as this information was not stated clearly in the manuscript. In line with the comments from Reviewer 1, the duration of all intervention components has been highlighted on page 7, line 32 of the manuscript and now reads: The intervention will provide a combination of the following: 1.
Financial incentives for every instance of CO verified smoking abstinence or reduction in smoking consumption from study enrolment until the birth of their baby. 2.
Counselling for smoking cessation as required from study enrolment to 12-weeks postpartum. 3.
NRT from enrolment until birth as part of the intervention, then to 12-weeks postpartum to assist relapse prevention. 5. Have the researchers considered the impact of the participants not physically obtaining their financial incentive upon demonstration of abstinence? Do you think only weekly will be 'instant' enough to sustain motivation? As described in Reviewer 1 comment 6 above, this was an important consideration in the development of this intervention. Bound by the inflexibility of fixed amount gift cards, we sought advice from CM researchers (both local and international) who suggested that instant feedback about incentives earned should be sufficient to maintain motivation. The use of feedback as a bridge between earning and receipt of earnings has been successfully trialled in the past and is supported by published data (see Reynolds, Dallery et al. 2008) .
Given that the reviewer has highlighted what will potentially be a common question, we have added some clarification around this. The incentives section on page 9, line 5 of the manuscript now reads: Incentives will be in the form of electronic gift cards from a major retail outlet that may be exchanged for groceries and general merchandise but restricted for purchases of alcohol and tobacco products. Due to the frequency of sampling and constraints of fixed amount gift cards, participants will receive written notification of incentive amounts earned immediately after submission of each CO sample. This methodology provides the positive reinforcement required to maintain behaviour change and has been successfully employed in an incentives program for adolescent smoking cessation.73 Actual earnings may be distributed weekly or accumulated and redeemed at a participant's request. 6. I am concerned about the appropriateness/practicability/feasibility of expecting these participants (likely low SES) to have reliable mobile data to provide video evidence so frequently. Is it possible to provide 2-4 'stations' in the hospital or nearby health clinic that these women can physically go to provide their evidence? Or conducting CO monitoring also during regular antenatal appointments? This concern is well placed and is an issue that we have carefully considered. Anecdotal evidence from our own clinics suggests that most women of child bearing age will own or have access to a smart phone or internet enabled device. Loan phones will be made available to those who don't, so that all women are able to take advantage of this valuable intervention. As a public health service, we were advised not to provide data directly to participants, so regular financial reimbursements will be provided instead to cover the cost of mobile data and time involved in participation. This is mentioned on page 13 of the protocol manuscript. 7. Can I strongly suggest seeking ethics to obtain infant health data up to 12 months of age? This is missing in the literature and allows for projections of these children's future lung health. Although paediatric lung health is an important issue, we may not have the resources to consider extending the timeframe for infant health data to 12-months. Time and inadequate human resources are potential barriers, but capacity will be reviewed and the issue given further consideration. We thank the reviewer for the suggestion. Minor comments 1.
Page 7, 19 -'do not' rather than 'don't' 2.
Page 8, 12 -remove 'is' from end of sentence 3.
Page 9, 50 -'and' rather than & 4.
Page 14, 14 -'Women in' rather than 'Women on' AND 'through' rather than 'though' at end of line Thank you for identifying these errors, all have been rectified as suggested.
VERSION 2 -REVIEW

REVIEWER
Allison Kurti University of Vermont USA REVIEW RETURNED 25-Aug-2019
GENERAL COMMENTS
The revised protocol is much improved. Authors have done a thoughtful and thorough job addressing prior concerns and providing greater detail where it was needed. I only have two minor comments:
1-Women can enter the study quite late in their pregnancy (up to 33 weeks)--If these are women who are both smoking and have additional comorbid substance use disorders, it seems possible that they might have very limited exposure to the treatment before delivery, depending on how early/preterm a given infant is delivered. Additionally, authors note that they expect that a substantial portion of women will enroll this late in their pregnancy. If these authors decide to leave this inclusion criterion as is, I would still recommend devising a plan to try and reach and enroll women earlier in their pregnancy, whether or not these efforts are detailed in this protocol.
2-The authors are using a baseline criterion to verify smoking status of > 3 ppm. The abstinence criterion for earning incentives is < or = 5 ppm. In other words, it appears that a smoker could have a baseline breath CO of 4 ppm and be enrolled in the study, as that CO level would meet criteria to verify smoker status in this protocol. However, that same person could also earn incentives for breath samples of 4 ppm and less. The minimum CO value for identifying someone as a current smoker should be higher than the cut point for determining abstinence and providing incentives.
VERSION 2 -AUTHOR RESPONSE Reviewer 1 Comments to Author:
1. Women can enter the study quite late in their pregnancy (up to 33 weeks)--If these are women who are both smoking and have additional comorbid substance use disorders, it seems possible that they might have very limited exposure to the treatment before delivery, depending on how early/preterm a given infant is delivered. Additionally, authors note that they expect that a substantial portion of women will enrol this late in their pregnancy. If these authors decide to leave this inclusion criterion as is, I would still recommend devising a plan to try and reach and enrol women earlier in their pregnancy, whether or not these efforts are detailed in this protocol.
The concerns of Reviewer 1 regarding late entry of women into tobacco and substance use treatment are acknowledged. The study is being implemented in a public health service where it is not uncommon for women with substance use concerns to delay seeking antenatal care until well into the second trimester of pregnancy. Efforts are consistently being made to improve uptake of antenatal services by this group. From a public health viewpoint, it is important to intervene at any point but the decision to recruit up to and including 32 weeks was also based on evidence that smoking cessation is valuable for women in their last trimester of pregnancy and can improve foetal growth (see Bernstein et al. 2005) . Despite the limited access to financial incentives, the later entry provides an opportunity for education, support and exposure to the provision and benefits of free NRT and these extend until 12-weeks into the postnatal period.
2. The authors are using a baseline criterion to verify smoking status of > 3 ppm. The abstinence criterion for earning incentives is < or = 5 ppm. In other words, it appears that a smoker could have a baseline breath CO of 4 ppm and be enrolled in the study, as that CO level would meet criteria to verify smoker status in this protocol. However, that same person could also earn incentives for breath samples of 4 ppm and less. The minimum CO value for identifying someone as a current smoker should be higher than the cut point for determining abstinence and providing incentives.
We recognise the discord raised by having a higher CO cut-off for abstinence than for eligibility but would argue that the purpose of each testing point are different. As a public health-based study, we believe that it is important to capture all smokers, even those registering as light smokers (i.e. those in the 4-6 COppm range) so that an eligibility CO of ≤3ppm is adequate for eligibility. A CO of ≤5ppm is considered a suitable cut-off to determine smoking status in pregnant smokers and does not exclude women impacted by passive smoking. We have noted the implications of this as a limitation on page 17 of the manuscript:
The study is has several limitations. For example, the differing CO cut-offs to determine eligibility and abstinence. Eligibility requires a CO of ≥3ppm to ensure the inclusion of all self-reported smokers, while the CO to determine smoking status is ≤5ppm. It is acknowledged that a small rise in CO may enable an incentive payment, however it is considered this would only apply to a minority of cases.
VERSION 3 -REVIEW
REVIEWER
Allison Kurti University of Vermont, USA REVIEW RETURNED 11-Oct-2019
GENERAL COMMENTS
Authors have done a Nice job addressing all concerns at this point, and I look forward to seeing their work in print!
